What does the evidence show about engineered Treg grafts?
The strongest direct evidence comes from a 2025 phase 2 trial where 44 patients received a purified donor Treg product after myeloablative conditioning. The 1-year incidence of moderate-to-severe chronic GVHD was 11%, and the primary endpoint—1-year GVHD-free relapse-free survival—was 64%, compared with 36% in a standard-of-care cohort [2]. In plain terms, adding Tregs more than halved the risk of chronic GVHD and nearly doubled the chance of being alive and free of both GVHD and relapse at one year.
A separate pediatric study using a Treg and conventional T-cell adoptive immunotherapy in haploidentical transplants reported only 1 out of 20 patients developing chronic GVHD, with a 60% GVHD-free relapse-free survival at a median follow-up of 2.1 years [4]. While small, this supports the feasibility of Treg-based approaches in a high-risk pediatric population.
How does Treg therapy compare with other GVHD prevention strategies?
Treg therapy is one of several approaches, and the evidence suggests it may be more effective than standard prophylaxis. For example, a large registry study (over 8,700 patients) found that post-transplant cyclophosphamide (PTCy) reduced chronic GVHD to 28.4% versus 31.4% with anti-thymocyte globulin (ATG) [1]. In contrast, the Treg trial reported an 11% rate of moderate-to-severe chronic GVHD [2], which is markedly lower, though direct comparisons across studies are limited by different patient populations and designs.
Other strategies that enhance Tregs, like low-dose IL-2 after haploidentical transplant, also reduced chronic GVHD incidence (P=0.018) and improved GVHD progression-free survival (P=0.025) in a small cohort trial [5]. This suggests that boosting Tregs—whether by infusion or by stimulating their growth—is a promising avenue, but the evidence base is still thinner than for established drugs.
What are the limitations and what's the catch?
The main catch is that Treg therapy is technically challenging and not yet widely available. Tregs are rare, and manufacturing a purified product requires specialized expertise, as highlighted in a 2026 review [6]. The phase 2 trial was single-center and open-label, and the comparator was a historical cohort, not a randomized control [2]. So while the results are promising, they need confirmation in larger, randomized trials.
Another caveat is that Treg therapy does not eliminate all GVHD. In the phase 2 trial, 7% still developed severe acute GVHD, and 11% had moderate-to-severe chronic GVHD [2]. Also, the pediatric study had a 15% non-relapse mortality rate [4], indicating that the approach is not without risks. Finally, the evidence is mixed on whether Tregs are the key factor—some studies show that other drugs like PTCy also increase Treg numbers [3], so the optimal way to harness Tregs is still being worked out.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2023 to 2026, 5 from 2024 or later, 6 in Q1 journals, collectively cited 63 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 52 papers retrieved from a database of over 500 million.
Sources used in this answer
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
In a large EBMT registry study (over 8,700 patients), PTCy prophylaxis was associated with lower chronic GVHD (28.4% vs 31.4%) and better overall survival (73.1% vs 65.9%) compared to ATG in matched unrelated donor transplants.
Donor regulatory T-cell therapy to prevent graft-versus-host disease
In a phase 2 trial of 44 patients, donor Treg therapy resulted in 11% moderate-to-severe chronic GVHD and 64% 1-year GVHD-free relapse-free survival, compared to 36% in a standard-of-care cohort.
Comparison of Regulatory T-Cell Subpopulations in Antithymocytic Globulin Versus Post-Transplant Cyclophosphamide for Preventing Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation—A Retrospective Study
In a retrospective study of 45 patients, PTCy was associated with higher effector Treg counts than ATG, and effector Treg counts inversely correlated with acute GVHD severity.
HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia
In a pediatric study of 20 patients, Treg and conventional T-cell adoptive immunotherapy led to only 1 case of chronic GVHD, with 60% GVHD-free relapse-free survival at median follow-up of 2.1 years.
Low dose of IL-2 application for graft-versus-host disease prophylaxis following haploidentical stem cell transplantation
In a cohort trial of 10 patients receiving low-dose IL-2 after haploidentical transplant, chronic GVHD incidence was lower (P=0.018) and GVHD progression-free survival was higher (P=0.025) compared to matched controls.
Regulatory T cell approaches for graft-versus-host disease prevention
A review highlights that Treg-based therapies are feasible and effective in early trials, but the rarity of Tregs is a limiting factor, with genetic engineering being a promising strategy to improve their function.